Data indicate durable immune response from bivalent booster after three months of follow-up
mRNA-1273.214 also demonstrated potent response to Omicron BA.2.75
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50 µg booster dose of mRNA-1273 in all participants regardless of prior infection. Superior performance against Omicron BA.1 was also durable, with higher antibody titers sustained through three months.
In addition, mRNA-1273.214 demonstrated significantly higher neutralizing antibody responses against Omicron BA.4/BA.5 compared to mRNA-1273 28 days after administration, as previously reported. Potent responses were also seen against Omicron BA.2.75 28 days after administration, suggesting that the bivalent booster elicits broad cross-neutralization against Omicron variants.
"Our bivalent boosters continue to demonstrate a strong, enduring response to COVID-19 variants of concern," said Stéphane Bancel, Chief Executive Officer of Moderna. "Clinical trial data now indicates that the superior immune response produced by our bivalent booster has durability for at least three months. As COVID-19 remains a global threat and a leading cause of death globally, this is an encouraging development, showing that a bivalent booster dose will offer important protection leading into the winter months."
Observed side effects of mRNA-1273.214 were similar or less severe than those of either a second or third dose of the original vaccine. Additionally, no new safety concerns were identified in the three-month follow-up.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.